Illinois Municipal Retirement Fund Has $2.49 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Illinois Municipal Retirement Fund boosted its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 47.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 33,957 shares of the biopharmaceutical company’s stock after purchasing an additional 10,895 shares during the period. Illinois Municipal Retirement Fund’s holdings in Halozyme Therapeutics were worth $2,490,000 as of its most recent SEC filing.

Several other large investors also recently modified their holdings of the stock. Empowered Funds LLC acquired a new stake in Halozyme Therapeutics in the 1st quarter valued at $755,000. Acadian Asset Management LLC bought a new stake in shares of Halozyme Therapeutics in the 1st quarter worth about $195,000. Envestnet Portfolio Solutions Inc. grew its holdings in shares of Halozyme Therapeutics by 46.2% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 16,506 shares of the biopharmaceutical company’s stock worth $859,000 after purchasing an additional 5,214 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new position in Halozyme Therapeutics during the 2nd quarter valued at about $2,051,000. Finally, Legacy Wealth Asset Management LLC boosted its position in Halozyme Therapeutics by 25.6% in the second quarter. Legacy Wealth Asset Management LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 1,010 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.

Insider Transactions at Halozyme Therapeutics

In related news, Director Bernadette Connaughton sold 2,000 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the sale, the director directly owned 40,123 shares in the company, valued at $2,818,640.75. This trade represents a 4.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Helen Torley sold 20,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total transaction of $1,522,400.00. Following the transaction, the chief executive officer directly owned 708,719 shares in the company, valued at $53,947,690.28. The trade was a 2.74% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 49,398 shares of company stock worth $3,650,592. Company insiders own 2.90% of the company’s stock.

Halozyme Therapeutics Stock Performance

Shares of Halozyme Therapeutics stock opened at $79.44 on Monday. The firm has a fifty day moving average of $70.85 and a two-hundred day moving average of $69.96. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The stock has a market capitalization of $9.34 billion, a price-to-earnings ratio of 16.72, a PEG ratio of 0.33 and a beta of 0.97. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22.

Analyst Ratings Changes

HALO has been the topic of several recent analyst reports. HC Wainwright reissued a “buy” rating on shares of Halozyme Therapeutics in a report on Thursday, January 29th. Citizens Jmp increased their target price on Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price target on Halozyme Therapeutics from $63.00 to $65.00 and gave the company a “neutral” rating in a report on Monday, October 27th. Citigroup restated a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. Finally, TD Cowen upped their target price on shares of Halozyme Therapeutics from $79.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, January 8th. Eight investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $78.80.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.